Peer review reports
From: Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities
Original Submission |
1 Dec 2020 |
Submitted |
Original manuscript
|
Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
Resubmission - Version 3 |
|
Submitted |
Manuscript version 3
|
Resubmission - Version 4 |
|
Submitted |
Manuscript version 4
|
Resubmission - Version 5 |
|
Submitted |
Manuscript version 5
|
20 Jan 2021 |
Reviewed |
Reviewer Report
|
2 Feb 2021 |
Reviewed |
Reviewer Report
|
23 Feb 2021 |
Author responded |
Author comments - Elizabeth Alexander
|
Resubmission - Version 6 |
23 Feb 2021 |
Submitted |
Manuscript version 6
|
24 Feb 2021 |
Reviewed |
Reviewer Report
|
Resubmission - Version 7 |
|
Submitted |
Manuscript version 7
|
Publishing |
17 Mar 2021 |
Editorially accepted |
|
8 May 2021 |
Article published |
10.1186/s12890-021-01472-z
|
Learn about peer review